Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Under Armour Inc Class A (UA) Price & Performance

Cassava Sciences IncTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Under Armour Inc Class A — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Under Armour Inc Class A trades at $4.74 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 52.5× Cassava Sciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Under Armour Inc Class A for 18 Days on average.

FLNAUA
Market Cap
$39.40M$2.07B
Volume
759,0182,680,141
Sector
HealthConsumer Cyclical
52-Week High
$4.64$7.88
52-Week Low
$0.68$3.96
Typical Hold Time
37 Days18 Days
Enterprise Value
-$43.28M$3.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.

The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.

Under Armour Inc Class A

Under Armour (UA) trades at $4.70, down 0.42% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company faces significant fundamental challenges with declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability metrics, including a -9.99% net income margin and -29.82% ROE. Recent earnings show volatility with two beats and one miss in the last four quarters, while cash flow remains negative across all categories.

The outlook remains challenging with declining revenue trends and persistent profitability issues offset by relatively low valuation multiples. Investment opportunity exists if management can stabilize sales and improve margins, but risks include continued consumer demand weakness and competitive pressures in the athletic apparel sector. Analyst sentiment is mixed with 41% buy ratings but growing concerns about the company's turnaround prospects.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
73% Buy27% Sell
Avg holding period · 37 Days
UA

No sentiment data available yet.

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA →